2022
Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry
Price MJ, Valderrábano M, Zimmerman S, Friedman DJ, Kar S, Curtis JP, Masoudi FA, Freeman JV. Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry. Circulation Cardiovascular Interventions 2022, 15: e011718. PMID: 35369701, PMCID: PMC9132377, DOI: 10.1161/circinterventions.121.011718.Peer-Reviewed Original ResearchConceptsAtrial appendage occlusionComposite of deathPericardial effusionAppendage occlusionSystemic embolismOdds ratioEarly postdischarge mortalityDual antiplatelet therapyLow serum albuminMean patient ageAdverse event ratesParoxysmal atrial fibrillationRisk of deathRisk-benefit ratioHospital strokeMean CHAPostdischarge mortalityVASc scoreWATCHMAN procedureAntiplatelet therapyIndex hospitalizationAdverse eventsPatient agePrimary outcomeVentricular function
2020
The NCDR Left Atrial Appendage Occlusion Registry
Freeman JV, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, Kavinsky CJ, Turi ZG, Akar J, Koutras C, Curtis JP, Masoudi FA. The NCDR Left Atrial Appendage Occlusion Registry. Journal Of The American College Of Cardiology 2020, 75: 1503-1518. PMID: 32238316, PMCID: PMC7205034, DOI: 10.1016/j.jacc.2019.12.040.Peer-Reviewed Original ResearchConceptsHospital adverse event ratesAdverse event ratesEvent ratesMean HAS-BLED scoreHAS-BLED scoreHospital adverse eventsMean patient ageAtrial appendage occlusionMedian annual numberMajor bleedingMean CHAMore comorbiditiesVASc scoreWATCHMAN procedureAdverse eventsCommon complicationPatient agePericardial effusionPivotal trialsAppendage occlusionRandomized trialsAtrial fibrillationPatient populationPresent patientPhysician characteristics
2015
Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?
Heidenreich PA, Tsai V, Bao H, Curtis J, Goldstein M, Curtis L, Hernandez A, Peterson P, Turakhia MP, Masoudi FA. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? JACC Heart Failure 2015, 3: 497-504. PMID: 25982109, DOI: 10.1016/j.jchf.2015.01.012.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionICD implantationOlder patientsTrial criteriaNew York Heart Association functional class IIIAge groupsSocial Security Death IndexPatients age 85Receipt of CRTFunctional class IIICardiac resynchronization therapyVentricular ejection fractionClinical trial criteriaDifferent age groupsPatient ageEjection fractionICD RegistryImproved survivalPrimary outcomeResynchronization therapyTherapy useDeath IndexMean ageClinical trialsRegistry data